RESUMEN
BACKGROUND: Magnetic resonance imaging (MRI) safety in patients with an epicardial cardiac implantable electronic device (CIED) is uncertain. OBJECTIVE: The purpose of this study was to assess the safety and adverse effects of MRI in patients who had surgically implanted epicardial CIED. METHODS: Patients with surgically implanted CIEDs who underwent MRI with an appropriate cardiology-radiology collaborative protocol between January 2008 and January 2021 were prospectively studied in 2 clinical centers. All patients underwent close cardiac monitoring through MRI procedures. Outcomes were compared between the epicardial CIED group and the matched non-MRI-conditional transvenous CIED group. RESULTS: Twenty-nine consecutive patients with epicardial CIED (41.4% male; mean age 43 years) underwent 52 MRIs in 57 anatomic regions. Sixteen patients had a pacemaker, 9 had a cardiac defibrillator or cardiac resynchronization therapy-defibrillator, and 4 had no device generator. No significant adverse events occurred in the epicardial or transvenous CIED groups. Battery life, pacing, sensing thresholds, lead impedance, and cardiac biomarkers were not significantly changed, except 1 patient had a transient decrease in atrial lead sensing function. CONCLUSION: MRI of CIEDs with epicardially implanted leads does not represent a greater risk than transvenous CIEDs when performed with a multidisciplinary collaborative protocol centered on patient safety.
Asunto(s)
Desfibriladores Implantables , Marcapaso Artificial , Humanos , Masculino , Adulto , Femenino , Desfibriladores Implantables/efectos adversos , Marcapaso Artificial/efectos adversos , Imagen por Resonancia Magnética/métodos , Corazón , Seguridad del PacienteRESUMEN
BACKGROUND: During magnetic resonance imaging (MRI), cardiac implantable electronic device (CIED) leads can be antennae to focus energy onto myocardium, leading to heating and arrhythmias. Clinical data on thoracic MRI safety for patients with legacy devices are limited. OBJECTIVE: The purpose of this study was to identify patients undergoing thoracic MRI with legacy devices, compare the incidence of adverse events of those patients with control patients undergoing brain MRI with legacy devices, and compare paired cardiac troponin T (cTnT) values. METHODS: In this single-center study, we reviewed a prospectively collected database of patients with CIED undergoing MRI from January 25, 2008, through February 28, 2017. RESULTS: Of 952 patients (1290 scans), 120 patients (12.6%) underwent 134 thoracic MRI scans with legacy CIEDs (median [range] age 61.98 [21.24-86.96] years; male 71.1%). Median (range; interquartile range [IQR]) age of leads across devices was 3.5 (1.6-7.1; 5.5) years; implantable cardioverter-defibrillators (ICDs) were oldest (median [range; IQR], 3.7 [1.1-8.0; 6.9] years). No difference was observed in incidence of adverse events between groups. Paired cTnT values were compared for 19 patients (19 scans) with no difference between pre- and postimaging values. No significant difference was present in device setting values before and after MRI (mean follow-up 72.5 days). Incidence of adverse events was no different after adjustment for ICD coil number. CONCLUSION: Thoracic MRI is relatively safe in an institutional multidisciplinary program. It does not represent greater risk than brain MRI for patients with legacy CIEDs.